Dexamethasone in the Treatment of COVID-19: Primus Inter Pares?
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread globally, becoming a huge public health challenge. Even though the vast majority of patients are asymptomatic, some patients present with pneumonia, acute respiratory distr...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-06-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/11/6/556 |
| _version_ | 1797530066189549568 |
|---|---|
| author | Vasiliki Romanou Evangelia Koukaki Vasiliki Chantziara Panagiota Stamou Alexandra Kote Ioannis Vasileiadis Antonia Koutsoukou Nikoletta Rovina |
| author_facet | Vasiliki Romanou Evangelia Koukaki Vasiliki Chantziara Panagiota Stamou Alexandra Kote Ioannis Vasileiadis Antonia Koutsoukou Nikoletta Rovina |
| author_sort | Vasiliki Romanou |
| collection | DOAJ |
| description | Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread globally, becoming a huge public health challenge. Even though the vast majority of patients are asymptomatic, some patients present with pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and death. It has been shown in several studies that the severity and clinical outcomes are related to dysregulated antiviral immunity and enhanced and persistent systemic inflammation. Corticosteroids have been used for the treatment of COVID-19 patients, as they are reported to elicit benefits by reducing lung inflammation and inflammation-induced lung injury. Dexamethasone has gained a major role in the therapeutic algorithm of patients with COVID-19 pneumonia requiring supplemental oxygen or on mechanical ventilation. Its wide anti-inflammatory action seems to form the basis for its beneficial action, taming the overwhelming “cytokine storm”. Amid a plethora of scientific research on therapeutic options for COVID-19, there are still unanswered questions about the right timing, right dosing, and right duration of the corticosteroid treatment. The aim of this review article was to summarize the data on the dexamethasone treatment in COVID-19 and outline the clinical considerations of corticosteroid therapy in these patients. |
| first_indexed | 2024-03-10T10:23:39Z |
| format | Article |
| id | doaj.art-962f5e184d034bf29e8dec8151762967 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-10T10:23:39Z |
| publishDate | 2021-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-962f5e184d034bf29e8dec81517629672023-11-22T00:13:35ZengMDPI AGJournal of Personalized Medicine2075-44262021-06-0111655610.3390/jpm11060556Dexamethasone in the Treatment of COVID-19: Primus Inter Pares?Vasiliki Romanou0Evangelia Koukaki1Vasiliki Chantziara2Panagiota Stamou3Alexandra Kote4Ioannis Vasileiadis5Antonia Koutsoukou6Nikoletta Rovina71st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens and “Sotiria” Chest Disease Hospital, 11527 Athens, Greece1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens and “Sotiria” Chest Disease Hospital, 11527 Athens, Greece1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens and “Sotiria” Chest Disease Hospital, 11527 Athens, Greece1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens and “Sotiria” Chest Disease Hospital, 11527 Athens, Greece1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens and “Sotiria” Chest Disease Hospital, 11527 Athens, Greece1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens and “Sotiria” Chest Disease Hospital, 11527 Athens, Greece1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens and “Sotiria” Chest Disease Hospital, 11527 Athens, Greece1st Department of Respiratory Medicine, Medical School, National and Kapodistrian University of Athens and “Sotiria” Chest Disease Hospital, 11527 Athens, GreeceCoronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly spread globally, becoming a huge public health challenge. Even though the vast majority of patients are asymptomatic, some patients present with pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and death. It has been shown in several studies that the severity and clinical outcomes are related to dysregulated antiviral immunity and enhanced and persistent systemic inflammation. Corticosteroids have been used for the treatment of COVID-19 patients, as they are reported to elicit benefits by reducing lung inflammation and inflammation-induced lung injury. Dexamethasone has gained a major role in the therapeutic algorithm of patients with COVID-19 pneumonia requiring supplemental oxygen or on mechanical ventilation. Its wide anti-inflammatory action seems to form the basis for its beneficial action, taming the overwhelming “cytokine storm”. Amid a plethora of scientific research on therapeutic options for COVID-19, there are still unanswered questions about the right timing, right dosing, and right duration of the corticosteroid treatment. The aim of this review article was to summarize the data on the dexamethasone treatment in COVID-19 and outline the clinical considerations of corticosteroid therapy in these patients.https://www.mdpi.com/2075-4426/11/6/556dexamethasonecorticosteroidsCOVID-19 |
| spellingShingle | Vasiliki Romanou Evangelia Koukaki Vasiliki Chantziara Panagiota Stamou Alexandra Kote Ioannis Vasileiadis Antonia Koutsoukou Nikoletta Rovina Dexamethasone in the Treatment of COVID-19: Primus Inter Pares? Journal of Personalized Medicine dexamethasone corticosteroids COVID-19 |
| title | Dexamethasone in the Treatment of COVID-19: Primus Inter Pares? |
| title_full | Dexamethasone in the Treatment of COVID-19: Primus Inter Pares? |
| title_fullStr | Dexamethasone in the Treatment of COVID-19: Primus Inter Pares? |
| title_full_unstemmed | Dexamethasone in the Treatment of COVID-19: Primus Inter Pares? |
| title_short | Dexamethasone in the Treatment of COVID-19: Primus Inter Pares? |
| title_sort | dexamethasone in the treatment of covid 19 primus inter pares |
| topic | dexamethasone corticosteroids COVID-19 |
| url | https://www.mdpi.com/2075-4426/11/6/556 |
| work_keys_str_mv | AT vasilikiromanou dexamethasoneinthetreatmentofcovid19primusinterpares AT evangeliakoukaki dexamethasoneinthetreatmentofcovid19primusinterpares AT vasilikichantziara dexamethasoneinthetreatmentofcovid19primusinterpares AT panagiotastamou dexamethasoneinthetreatmentofcovid19primusinterpares AT alexandrakote dexamethasoneinthetreatmentofcovid19primusinterpares AT ioannisvasileiadis dexamethasoneinthetreatmentofcovid19primusinterpares AT antoniakoutsoukou dexamethasoneinthetreatmentofcovid19primusinterpares AT nikolettarovina dexamethasoneinthetreatmentofcovid19primusinterpares |